Kanuma (Sebelipase Alfa)

Sebelipase Alfa is a recombinant form of human lysosomal acid lipase. After intravenous infusion, it is taken up by cells and delivered to lysosomes, where it hydrolyzes cholesteryl esters and triglycerides, thereby decreasing intracellular lipid storage and restoring normal lipid metabolism.

The dose of Kanuma is individualized. The prescribing clinician determines the appropriate amount and infusion schedule based on the patient’s weight, disease severity, and clinical response.

Safety data for Kanuma in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Kanuma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Kanuma is a recombinant enzyme replacement therapy that directly replaces deficient lysosomal acid lipase, whereas alternative approaches may include substrate reduction or supportive care. Kanuma targets the underlying enzyme deficiency, offering a disease‑modifying effect not achieved by symptomatic treatments alone.

Kanuma should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking to maintain product stability.

Kanuma is given as an intravenous infusion. The infusion is performed by a qualified healthcare professional in a clinical setting, with monitoring for any infusion‑related reactions during and after the administration.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, significant liver enzyme elevations, and rare hematologic abnormalities like thrombocytopenia. Prompt medical attention is required if any of these events occur.

Kanuma is contraindicated in patients with known hypersensitivity to Sebelipase Alfa or any component of the formulation. Caution is also advised for individuals with uncontrolled severe infections or those receiving live vaccines.